Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Advances in Gastroenterology and Metabolism
share announcement

Advances in Gastroenterology and Metabolism

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Advances in Metabolomics".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 9578

Special Issue Editor

Dr. Katsuyuki Miyabe

E-Mail Website
Guest Editor
Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Aichi 466-8650, Japan
Interests: metabolome; IgG4-related disease; microbiome; cholangiocarcinoma

Special Issue Information

Dear Colleagues,

With the advancement of biotechonologies, the metabolomic approach has been essential in the medical field to explore the mechanisms of biological phenomena, classify patient characterisation, and monitor direct reposenses to therapies, all of which will lead to the establishment of personalized medicine. This type of study is expanding a variety of fields and gastroenteriolocal studies using metabolimics with or without the study of trans-omics, including microbiome or exosome analyses, and they have been shown to be of great value in regard to elucidating biological response in one of the main organs in the human body.

This Special Issue of Metabolites, " Advances in Gastroenterology and Metabolism" will be dedicated to the publication of the cutting-edge of metabolimics studies of gastrointestinal organs, including the alimentar tract, liver, bile duct, and pancreas. The Special Issue will cover a wide variety of issues relevant to metabolimic studies, including biotechonological advancement, the clarified mechanism of metabolimics in gastrointestinal disorders, novel biomarkers for diagnosis, and promising pharmacoceutical development based on the metabomics approach. Manuscripts dealing with other challenging issues are also highly desired.

Dr. Katsuyuki Miyabe
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut metabolomics
  • liver metabolomics
  • pancreatic metabolomics
  • metabolomics of gastroinitestinal cancers
  • mechanism of metabolimics in the gastrointestinal disorders
  • biomarkers for the diagnosis of gastrointestinal disorders
  • pharmacoceutical development in the gastrointestinal disorders

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1022 KiB  
Article
A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients
by Oiana Telleria, Oihane E. Alboniga, Marc Clos-Garcia, Beatriz Nafría-Jimenez, Joaquin Cubiella, Luis Bujanda and Juan Manuel Falcón-Pérez
Metabolites 2022, 12(6), 550; https://doi.org/10.3390/metabo12060550 - 15 Jun 2022
Cited by 10 | Viewed by 2616
Abstract
Accurate diagnosis of colorectal cancer (CRC) still relies on invasive colonoscopy. Noninvasive methods are less sensitive in detecting the disease, particularly in the early stage. In the current work, a metabolomics analysis of fecal samples was carried out by ultra-high-performance liquid chromatography–tandem mass [...] Read more.
Accurate diagnosis of colorectal cancer (CRC) still relies on invasive colonoscopy. Noninvasive methods are less sensitive in detecting the disease, particularly in the early stage. In the current work, a metabolomics analysis of fecal samples was carried out by ultra-high-performance liquid chromatography–tandem mass spectroscopy (UPLC-MS/MS). A total of 1380 metabolites were analyzed in a cohort of 120 fecal samples from patients with normal colonoscopy, advanced adenoma (AA) and CRC. Multivariate analysis revealed that metabolic profiles of CRC and AA patients were similar and could be clearly separated from control individuals. Among the 25 significant metabolites, sphingomyelins (SM), lactosylceramides (LacCer), secondary bile acids, polypeptides, formiminoglutamate, heme and cytidine-containing pyrimidines were found to be dysregulated in CRC patients. Supervised random forest (RF) and logistic regression algorithms were employed to build a CRC accurate predicted model consisting of the combination of hemoglobin (Hgb) and bilirubin E,E, lactosyl-N-palmitoyl-sphingosine, glycocholenate sulfate and STLVT with an accuracy, sensitivity and specificity of 91.67% (95% Confidence Interval (CI) 0.7753–0.9825), 0.7 and 1, respectively. Full article
(This article belongs to the Special Issue Advances in Gastroenterology and Metabolism)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

19 pages, 2346 KiB  
Review
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
by Marta Moreno-Torres, Guillermo Quintás and José V. Castell
Metabolites 2022, 12(6), 564; https://doi.org/10.3390/metabo12060564 - 19 Jun 2022
Cited by 17 | Viewed by 2833
Abstract
Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical [...] Read more.
Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical industry. The current biochemical parameters for the detection of DILI are based on enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP)) and bilirubin serum levels that are not specific of DILI and therefore there is an increasing interest on novel, specific, DILI biomarkers discovery. Metabolomics has emerged as a tool with a great potential for biomarker discovery, especially in disease diagnosis, and assessment of drug toxicity or efficacy. This review summarizes the multistep approaches in DILI biomarker research and discovery based on metabolomics and the principal outcomes from the research performed in this field. For that purpose, we have reviewed the recent scientific literature from PubMed, Web of Science, EMBASE, and PubTator using the terms “metabolomics”, “DILI”, and “humans”. Despite the undoubted contribution of metabolomics to our understanding of the underlying mechanisms of DILI and the identification of promising novel metabolite biomarkers, there are still some inconsistencies and limitations that hinder the translation of these research findings into general clinical practice, probably due to the variability of the methods used as well to the different mechanisms elicited by the DILI causing agent. Full article
(This article belongs to the Special Issue Advances in Gastroenterology and Metabolism)
►▼ Show Figures

Figure 1

16 pages, 3590 KiB  
Review
Renin–Angiotensin System in Liver Metabolism: Gender Differences and Role of Incretins
by Zainab Mastoor, Yolanda Diz-Chaves, Lucas C. González-Matías and Federico Mallo
Metabolites 2022, 12(5), 411; https://doi.org/10.3390/metabo12050411 - 03 May 2022
Cited by 8 | Viewed by 3592
Abstract
The impaired hepatic lipids and carbohydrates metabolism result in various metabolic disorders, including obesity, diabetes, insulin resistance, hyperlipidemia and metabolic syndrome. The renin–angiotensin system (RAS) has been identified in the liver and it is now recognized as an important modulator of body metabolic [...] Read more.
The impaired hepatic lipids and carbohydrates metabolism result in various metabolic disorders, including obesity, diabetes, insulin resistance, hyperlipidemia and metabolic syndrome. The renin–angiotensin system (RAS) has been identified in the liver and it is now recognized as an important modulator of body metabolic processes. This review is intended to provide an update of the impact of the renin–angiotensin system on lipid and carbohydrate metabolism, regarding gender difference and prenatal undernutrition, specifically focused on the role of the liver. The discovery of angiotensin-converting enzyme 2 (ACE2) has renewed interest in the potential therapeutic role of RAS modulation. RAS is over activated in non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma. Glucagon-like peptide-1 (GLP-1) has been shown to modulate RAS. The GLP-I analogue liraglutide antagonizes hepatocellular steatosis and exhibits liver protection. Liraglutide has a negative effect on the ACE/AngII/AT1R axis and a positive impact on the ACE2/Ang(1-7)/Mas axis. Activation of the ACE2/Ang(1-7)/Mas counter-regulatory axis is able to prevent liver injuries. Angiotensin(1-7) and ACE2 shows more favorable effects on lipid homeostasis in males but there is a need to do more investigation in female models. Prenatal undernutrition exerts long-term effects in the liver of offspring and is associated with a number of metabolic and endocrine alterations. These findings provide a novel therapeutic regimen to prevent and treat many chronic diseases by accelerating the effect of the ACE2/Ang1-7/Mas axis and inhibiting the ACE/AngII/AT1R axis. Full article
(This article belongs to the Special Issue Advances in Gastroenterology and Metabolism)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop